Drugs / TQB3824
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05028218 | Aug 2021 → Aug 2024 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3824 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028218 ↗ |
| Action | Inhibit | “TQB3824 blocks function of a specific protein called Cell Division Cycle 7 (CDC7) kinase in the human body” NCT05028218 ↗ |
| Route | Oral | “TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle” NCT05028218 ↗ |
| Target | CDC7 | “TQB3824 blocks function of a specific protein called Cell Division Cycle 7 (CDC7) kinase in the human body” NCT05028218 ↗ |